Alloy HRT: Specific Patient Profiles Who Should Avoid It (or Use Caution)

What Alloy Is and How Its Prescribing Model Works

Alloy markets itself as a fast, affordable path to menopause hormone therapy. The platform uses an online symptom questionnaire, optional video or asynchronous messaging with a clinician, and ships prescriptions directly to the patient. There is no mandatory physical examination, no required baseline bloodwork in the standard flow, and no in-person follow-up built into the default care pathway.

That model works for a narrow, well-defined population. It does not work for everyone.

The Standard Alloy Intake Process

The intake form asks about personal and family history of hormone-sensitive cancers, blood clots, cardiovascular disease, and liver conditions. Accuracy depends entirely on what the patient self-reports. A 2021 analysis published in JAMA Internal Medicine found that telehealth platforms prescribing hormones asynchronously had meaningfully higher rates of incomplete risk-factor documentation compared with synchronous video visits ([1]).

What the Platform Does Not Do

Alloy does not require a pelvic exam, Pap smear, mammogram confirmation, or transvaginal ultrasound before prescribing systemic estrogen. The North American Menopause Society (NAMS) 2023 Position Statement states: "Individualized assessment of each woman's risk factors and symptoms should guide the decision to use MHT, the type of therapy, and the duration of use" ([2]). Self-reported questionnaires alone cannot substitute for that assessment in higher-risk individuals.

Patient Profile 1: Personal History of Hormone-Sensitive Cancers

Women with a personal history of breast cancer, endometrial cancer, or ovarian cancer should not start systemic HRT through Alloy. Full stop.

The 2023 NAMS Position Statement explicitly flags prior hormone-sensitive malignancy as a condition requiring specialist involvement before any HRT decision ([2]). The Women's Health Initiative (WHI) estrogen-plus-progestin trial (N=16,608) found a hazard ratio of 1.26 for invasive breast cancer in the combined-hormone arm after 5.6 years of follow-up ([3]). That signal does not mean HRT is universally off-limits for breast cancer survivors. It means the decision requires oncology input, detailed receptor status review, and a physical examination. An online intake form cannot deliver any of those.

Why the Risk Is Higher in Asynchronous Telehealth

Breast cancer survivors on aromatase inhibitors, for example, face drug-interaction considerations that a questionnaire is unlikely to capture. A platform that cannot review pathology reports or current oncology treatment plans should not be the prescriber of record for this group.

Endometrial Cancer History

Women with a history of endometrial cancer need transvaginal ultrasound monitoring and uterine assessment before systemic estrogen is considered. Alloy's standard workflow provides neither. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 specifies that HRT in endometrial cancer survivors requires individualized gynecologic oncology consultation ([4]).

Patient Profile 2: Personal or Family History of Venous Thromboembolism

Women with a personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE), or with a known thrombophilia such as Factor V Leiden or prothrombin gene mutation, carry elevated clot risk with oral estrogen.

The WHI trial reported a hazard ratio of 2.11 for DVT and 1.61 for PE with conjugated equine estrogen plus medroxyprogesterone acetate compared with placebo ([3]). Transdermal estradiol carries substantially lower thrombotic risk than oral formulations. A 2016 case-control study in the BMJ (N=80,396 women) found transdermal estradiol did not significantly increase VTE risk, while oral estrogen raised it roughly twofold ([5]).

The Prescribing Gap

Alloy does offer transdermal options, which is clinically appropriate. The concern is that the platform's intake process cannot reliably identify all thrombophilia risk. A family history question on a form does not equal a Factor V Leiden genotype panel or a hematology consultation. Women who know they have a thrombophilia should have their prescribing managed by a provider who can review lab results and coordinate with hematology when needed.

What to Do Instead

Hematology or a menopause-specialist ob-gyn experienced in thrombophilia management is the right first stop for this profile. Once a transdermal regimen is established and monitored, some patients may eventually transition to a lower-intensity telehealth model for refills. Starting there is the problem.

Patient Profile 3: Uncontrolled Cardiovascular Disease or Recent Cardiac Event

Women who have had a myocardial infarction, stroke, or TIA within the past 12 months, or who have active uncontrolled hypertension, should not initiate HRT through a platform that lacks baseline cardiovascular assessment.

The American Heart Association's 2020 scientific statement on menopause and cardiovascular risk notes that HRT initiation more than 10 years after menopause onset or after age 60 carries a higher coronary artery disease risk and should follow careful cardiovascular workup ([6]). The WHI trial's coronary heart disease hazard ratio was 1.29 in the combined-hormone arm, with the highest risk concentrated in women who were older or further from menopause onset ([3]).

The Timing Problem

Age at menopause onset matters. Women who are more than 10 years post-menopause or older than 60 at HRT initiation sit in a higher-risk category per the "timing hypothesis" supported by re-analysis of WHI data ([7]). Alloy's intake form asks date of last menstrual period, but does not include a mandatory cardiovascular risk score calculation or EKG requirement. A clinician reviewing the form asynchronously cannot reliably stratify that risk without additional workup.

Blood Pressure Monitoring

Oral estrogen can raise blood pressure in susceptible women. Transdermal estradiol has a more favorable blood pressure profile, but neither route is appropriate to initiate without knowing current blood pressure status. Alloy does not require documented blood pressure measurement before prescribing.

Patient Profile 4: Unexplained Uterine Bleeding

Any woman with a uterus who is experiencing unexplained vaginal bleeding must be evaluated with endometrial biopsy or transvaginal ultrasound before starting systemic estrogen plus progestogen. This is non-negotiable per ACOG Practice Bulletin No. 128 on diagnosis of abnormal uterine bleeding ([8]).

Alloy's intake form does ask about abnormal bleeding. If a patient answers "yes," the platform may decline to prescribe or escalate. The problem is that patients who are uncertain about whether their bleeding is "abnormal" may not flag it, and the form cannot probe with the clinical follow-up questions that an in-person visit would generate.

Endometrial Hyperplasia Risk

Adding estrogen without adequate progestogen in a woman with a uterus raises endometrial hyperplasia and cancer risk. The relative risk of endometrial cancer with unopposed estrogen use for 10 or more years is approximately 10-fold higher than in non-users, per data summarized in a Cochrane review ([9]). The standard of care is combined estrogen-progestogen or progestogen-only therapy for women with an intact uterus, which Alloy does offer. The gap is in diagnosing whether existing abnormal bleeding represents a lesion that must be treated before HRT begins.

Patient Profile 5: Active Liver Disease or Significantly Impaired Liver Function

Oral estrogen is metabolized hepatically. Women with active hepatitis, cirrhosis, or other significant liver disease should not use oral estrogen formulations without liver-function testing and hepatology input ([10]).

Transdermal estradiol bypasses first-pass hepatic metabolism and is considered safer in women with liver dysfunction, but identifying who has meaningful liver disease requires lab work. Alloy does not mandate liver-function panels as part of its standard intake. A woman with previously undiagnosed non-alcoholic fatty liver disease who presents with menopausal symptoms might receive oral estradiol without any signal that her liver function needs checking first.

Patient Profile 6: Active or Recent Breast Symptoms Requiring Workup

A palpable breast mass, new nipple discharge, or a mammogram flagged as BI-RADS 4 or higher requires diagnostic resolution before systemic estrogen is started. Adding estrogen to an unresolved breast finding is not appropriate ([2]).

Alloy's intake form asks whether the patient has had a recent mammogram. It does not review imaging reports. A patient who says "yes, I had one recently" but whose mammogram showed a BI-RADS 4 lesion awaiting biopsy could, in theory, pass through the intake process without that detail being caught.

The framework below summarizes the decision logic a clinician would apply before clearing a patient for D2C HRT:

| Risk Factor | Appropriate for Alloy? | Required Before HRT | |---|---|---| | Healthy woman, age 45-60, uncomplicated menopause | Yes, with monitoring | Symptom review, BP check | | Personal history of breast cancer | No | Oncology clearance, receptor status | | Known thrombophilia | No | Hematology consult, transdermal-only plan | | Unresolved uterine bleeding | No | Endometrial biopsy or TVUS | | Active liver disease | No | LFTs, hepatology input | | Recent MI or stroke (<12 months) | No | Cardiology clearance | | BI-RADS 4+ mammogram pending biopsy | No | Diagnostic resolution first | | Age >60 with no prior HRT use | Caution | Cardiovascular risk scoring |

What the Complaint Record Shows

Alloy has received consumer complaints related to billing disputes, difficulty canceling subscriptions, and inconsistent clinician responsiveness. The Better Business Bureau profile for Alloy as of mid-2025 shows the company is not BBB-accredited ([11]). Several complaints on the BBB site describe delays in prescription refills and difficulty reaching clinical staff.

These are not direct safety complaints, but they point to a structural issue. A platform where patients struggle to contact their prescribing clinician creates gaps in the ability to report new symptoms, medication side effects, or emerging contraindications after prescribing begins.

Regulatory Standing

Alloy prescribes FDA-approved hormone products, which is appropriate. The platform's prescribers are licensed in the states where they practice. LegitScript, the pharmacy verification service, has not listed Alloy as a rogue or non-compliant pharmacy operation ([12]). From a regulatory standpoint, Alloy appears to operate within the law.

The safety concerns described in this article are clinical judgment issues, not legal violations. A platform can be legally compliant and still be a poor fit for patients with complex medical histories.

State Medical Board Considerations

Telehealth prescribing regulations vary by state. Some states require an initial synchronous visit before controlled substances or hormones can be prescribed. Patients should verify that their state allows asynchronous or questionnaire-based prescribing for hormones before using Alloy, as the legal framework may differ from what the platform's website implies ([13]).

Is Alloy Legit? A Balanced Assessment

Alloy is a legitimate, licensed telehealth operation. It prescribes FDA-approved medications through licensed clinicians. For a healthy woman between 45 and 60 with classic vasomotor symptoms, no personal cancer history, no thrombophilia, controlled blood pressure, and a uterus being managed with combined therapy, Alloy represents a reasonable, lower-cost access point to care that remains chronically under-delivered in traditional healthcare settings.

Where the Legitimacy Concern Arises

The platform's design optimizes for speed and convenience. That is a feature for low-risk patients and a hazard for high-risk ones. The intake questionnaire is not a physical exam. Asynchronous review is not equivalent to a clinical encounter in which a physician can ask follow-up questions, review records, or perform an examination.

A 2023 editorial in Menopause: The Journal of the North American Menopause Society noted that "the rapid proliferation of telehealth menopause platforms has improved access for many women while simultaneously raising concerns about adequate risk stratification in the absence of standardized clinical protocols" ([14]).

The Access Argument

Roughly 1.3 million women in the United States reach menopause each year, per CDC data ([15]). A 2020 survey published in Menopause found that fewer than 25% of ob-gyns felt adequately trained to manage menopause, and average wait times for a menopause specialist exceeded 3 months in many urban markets ([16]). Alloy and platforms like it exist partly because the traditional system has failed to meet demand.

That access argument is real. It does not change the clinical math for the patient profiles identified above.

When to Choose an In-Person Menopause Specialist Instead

Women who fall into any of the high-risk profiles described above should seek a menopause-certified physician or nurse practitioner through the NAMS provider locator, a board-certified reproductive endocrinologist, or their ob-gyn for HRT initiation. After a safe regimen is established and documented in-person, some of these patients may be appropriate for telehealth management of ongoing refills, but that transition requires an explicit handoff.

The Menopause Society (formerly NAMS) maintains a "Menopause Practitioner" certification (NCMP) for clinicians who have demonstrated competency specifically in menopause management. Finding a NCMP-certified provider is a reasonable starting point for anyone whose history includes the risk factors described above ([2]).